✦ LIBER ✦

The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up

✍ Scribed by C. W. LEES; A. I. ALI; A. I. THOMPSON; G.-T. HO; R. O. FORSYTHE; L. MARQUEZ; C. J. COCHRANE; S. AITKEN; J. FENNELL; P. ROGERS; A. G. SHAND; I. D. PENMAN; K. R. PALMER; D. C. WILSON; I. D. R. ARNOTT; J. SATSANGI

Book ID: 108605508
Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 192 KB
Volume: 29
Category: Article
ISSN: 0269-2813
DOI: 10.1111/j.1365-2036.2008.03882.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Psoriasis associated with anti-tumour ne

Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature

✍ G. Cullen; D. Kroshinsky; A. S. Cheifetz; J. R. Korzenik 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 192 KB

Differences in the incidence of flares o

Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti–tumor necrosis factor α agents

✍ Braun, J. ;Baraliakos, X. ;Listing, J. ;Davis, J. ;van der Heijde, D. ;Haibel, H 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB 👁 2 views

## Abstract ## Objective Ankylosing spondylitis (AS) and inflammatory bowel disease (IBD) are clinically and pathologically linked. Anti–tumor necrosis factor (anti‐TNF) agents are efficacious in treating AS, but not all are equally effective in treating IBD (Crohn's disease [CD] and ulcerative co